胸膜痛治疗市场 - 全球产业规模、份额、趋势、机会和预测，按诊断、按治疗、按给药方式、按最终用户、按地区和竞争进行细分，2020-2030 年预测

2024 年全球胸膜痛治疗市场价值为 1.4355 亿美元，预计在预测期内将稳定成长，到 2030 年的复合年增长率为 5.25%。全球胸膜痛治疗市场代表了医疗保健产业内一个快速发展的领域，其发展得益于诊断技术的进步和疾病盛行率的上升。胸膜痛，通常被称为“魔鬼的抓握”，是一种主要由肠病毒（特别是柯萨奇病毒）引起的病毒感染，其特征是急性胸痛和肌痛，主要影响儿童和年轻人。

市场成长得益于分子诊断技术的重大发展，特别是聚合酶炼式反应 (PCR) 和次世代定序 (NGS)，它们大大提高了诊断精度并缩短了检测时间。这些创新增强了早期识别能力，并允许及时干预，最终改善患者的治疗效果。

然而，市场面临着巨大的挑战，主要是由于缺乏有针对性的抗病毒疗法和诊断复杂性。缺乏专门的治疗选择导致对症状管理的依赖，从而限制了治疗进展的范围。此外，胸膜痛的临床表现常常与心臟和呼吸系统疾病相似，导致经常误诊和延迟或不适当的治疗。儘管存在这些障碍，但全球胸膜痛治疗市场仍将持续成长，这得益于发病率的上升和对诊断研究的持续投资。解决治疗差距和改进诊断方案对于释放市场的全部潜力和加强患者护理至关重要。

主要市场驱动因素

医学研究和技术的进步

主要市场挑战

认识不足和误诊

主要市场趋势

诊断技术的进步

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：顾客之声

第五章：胸膜痛治疗市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 透过诊断（血液检查、培养检查、X光检查）
  • 依治疗（镇痛药或止痛药、免疫球蛋白）
  • 依给药方式（口服、注射或输液）
  • 按最终用户（医院、药房、其他）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第六章：北美胸膜痛治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 加拿大
  • 墨西哥

第 7 章：欧洲胸膜痛治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 英国
  • 义大利
  • 法国
  • 西班牙

第八章：亚太胸膜痛治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：南美洲胸膜痛治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 阿根廷
  • 哥伦比亚

第十章：中东与非洲胸膜痛治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 最新动态
• 产品发布
• 合併与收购

第 13 章：全球胸膜痛治疗市场：SWOT 分析

第 14 章：竞争格局

• Bristol-Myers Squibb Co
• F. Hoffmann-La Roche Ltd
• Pfizer Inc
• Sanofi SA
• Johnson & Johnson
• Merck & Co Inc.
• GlaxoSmithKline PLC
• Reckitt Benckiser PLC
• Bayer AG
• Novartis AG

第 15 章：策略建议

Global Pleurodynia Treatment Market was valued at USD 143.55 Million in 2024 and is anticipated to project steady growth in the forecast period with a CAGR of 5.25% through 2030. The Global Pleurodynia Treatment Market represents a rapidly evolving segment within the healthcare industry, driven by advancements in diagnostic technology and increasing disease prevalence. Pleurodynia, commonly referred to as "Devil's Grip," is a viral infection primarily caused by enteroviruses, notably Coxsackievirus, and is characterized by acute chest pain and myalgia, predominantly affecting children and young adults.

Market growth is underpinned by significant developments in molecular diagnostics, particularly Polymerase Chain Reaction (PCR) and Next-Generation Sequencing (NGS), which have substantially improved diagnostic precision and reduced the time to detection. These innovations enhance early-stage identification and allow for timely intervention, ultimately improving patient outcomes.

However, the market faces considerable challenges, primarily due to the lack of targeted antiviral therapies and diagnostic complexities. The absence of specialized treatment options results in a reliance on symptomatic management, limiting the scope of therapeutic advancements. Furthermore, pleurodynia's clinical presentation often mimics cardiac and respiratory disorders, leading to frequent misdiagnosis and delayed or inappropriate treatment. Despite these hurdles, the global pleurodynia treatment market is positioned for sustained growth, fueled by rising incidence rates and continued investment in diagnostic research. Addressing treatment gaps and refining diagnostic protocols will be critical to unlocking the market's full potential and enhancing patient care.

Key Market Drivers

Advancements in Medical Research and Technology

In recent years, the healthcare industry has experienced an unprecedented surge in medical research and technological advancements. These innovations have played a pivotal role in driving the growth of the Global Pleurodynia Treatment Market. Cutting-edge diagnostic tools and therapeutic options have been developed, significantly enhancing the management of pleurodynia.

One notable advancement is the utilization of molecular diagnostic techniques, such as Polymerase Chain Reaction (PCR) tests. These tests have revolutionized the accuracy and speed of pleurodynia diagnosis. By detecting the viral RNA in patient samples, PCR tests provide rapid and precise results, enabling healthcare professionals to initiate treatment promptly. NGS has also emerged as a game-changer in pleurodynia diagnosis and research. This high-throughput sequencing technology allows for the comprehensive analysis of viral genomes, aiding in the understanding of pleurodynia strains and their genetic variations. Such insights are invaluable for the development of targeted treatments.

Key Market Challenges

Limited Awareness and Misdiagnosis

One of the primary challenges hindering the growth of the Global Pleurodynia Treatment Market is the limited awareness among the general population. Pleurodynia, often referred to as "Devil's Grip," is a relatively uncommon viral infection. Many individuals may not recognize its symptoms, which can mimic other, more common ailments. This lack of awareness results in delayed diagnosis and treatment, impacting market growth.

The symptoms of pleurodynia, including severe chest pain and muscle aches, overlap with those of other respiratory and musculoskeletal conditions. Healthcare professionals may misdiagnose pleurodynia as conditions like pneumonia or muscular strain, leading to inappropriate treatment. Accurate and timely diagnosis is crucial for the effective management of pleurodynia, and misdiagnosis can slow down market expansion.

Key Market Trends

Advancements in Diagnostic Technologies

One significant trend in the Global Pleurodynia Treatment Market is the rapid advancement of diagnostic technologies. Molecular diagnostic techniques, such as Polymerase Chain Reaction (PCR) and next-generation sequencing (NGS), have gained prominence. These techniques enable healthcare professionals to detect pleurodynia with higher accuracy and speed by identifying viral RNA in patient samples. The adoption of these cutting-edge diagnostic tools is improving the efficiency of pleurodynia diagnosis and facilitating early treatment initiation.

Another notable trend is the development of point-of-care testing for pleurodynia. Point-of-care tests provide rapid results at the patient's bedside or in outpatient settings. These tests are particularly beneficial in regions with limited access to advanced healthcare facilities. The availability of point-of-care tests is expected to enhance the early detection and management of pleurodynia.

Key Market Players

• Bristol-Myers Squibb Co
• F. Hoffmann-La Roche Ltd
• Pfizer Inc
• Sanofi SA
• Johnson & Johnson
• Merck & Co Inc.
• GlaxoSmithKline PLC
• Reckitt Benckiser PLC
• Bayer AG
• Novartis AG

Report Scope:

In this report, the Global Pleurodynia Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pleurodynia Treatment Market, By Diagnosis:

• Blood test
• Culture test
• X-ray

Pleurodynia Treatment Market, By Treatment:

• Analgesics or Painkillers
• Immunoglobulin

Pleurodynia Treatment Market, By Mode of Administration:

• Oral
• Injections or infusion

Pleurodynia Treatment Market, By End-User:

• Hospitals
• Pharmacy
• Others

Pleurodynia Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pleurodynia Treatment Market.

Available Customizations:

Global Pleurodynia Treatment market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Pleurodynia Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Diagnosis (Blood test, Culture test, X-ray)
  • 5.2.2. By Treatment (Analgesics or Painkillers, Immunoglobulin)
  • 5.2.3. By Mode of Administration (Oral, Injections or infusion)
  • 5.2.4. By End-User (Hospitals, Pharmacy, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Pleurodynia Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Diagnosis
  • 6.2.2. By Treatment
  • 6.2.3. By Mode of Administration
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Pleurodynia Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Diagnosis
      • 6.3.1.2.2. By Treatment
      • 6.3.1.2.3. By Mode of Administration
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Pleurodynia Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Diagnosis
      • 6.3.2.2.2. By Treatment
      • 6.3.2.2.3. By Mode of Administration
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Pleurodynia Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Diagnosis
      • 6.3.3.2.2. By Treatment
      • 6.3.3.2.3. By Mode of Administration
      • 6.3.3.2.4. By End User

7. Europe Pleurodynia Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Diagnosis
  • 7.2.2. By Treatment
  • 7.2.3. By Mode of Administration
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Pleurodynia Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Diagnosis
      • 7.3.1.2.2. By Treatment
      • 7.3.1.2.3. By Mode of Administration
      • 7.3.1.2.4. By End User
  • 7.3.2. United Kingdom Pleurodynia Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Diagnosis
      • 7.3.2.2.2. By Treatment
      • 7.3.2.2.3. By Mode of Administration
      • 7.3.2.2.4. By End User
  • 7.3.3. Italy Pleurodynia Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Diagnosis
      • 7.3.3.2.2. By Treatment
      • 7.3.3.2.3. By Mode of Administration
      • 7.3.3.2.4. By End User
  • 7.3.4. France Pleurodynia Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Diagnosis
      • 7.3.4.2.2. By Treatment
      • 7.3.4.2.3. By Mode of Administration
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Pleurodynia Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Diagnosis
      • 7.3.5.2.2. By Treatment
      • 7.3.5.2.3. By Mode of Administration
      • 7.3.5.2.4. By End User

8. Asia-Pacific Pleurodynia Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Diagnosis
  • 8.2.2. By Treatment
  • 8.2.3. By Mode of Administration
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Pleurodynia Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Diagnosis
      • 8.3.1.2.2. By Treatment
      • 8.3.1.2.3. By Mode of Administration
      • 8.3.1.2.4. By End User
  • 8.3.2. India Pleurodynia Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Diagnosis
      • 8.3.2.2.2. By Treatment
      • 8.3.2.2.3. By Mode of Administration
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Pleurodynia Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Diagnosis
      • 8.3.3.2.2. By Treatment
      • 8.3.3.2.3. By Mode of Administration
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Pleurodynia Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Diagnosis
      • 8.3.4.2.2. By Treatment
      • 8.3.4.2.3. By Mode of Administration
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Pleurodynia Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Diagnosis
      • 8.3.5.2.2. By Treatment
      • 8.3.5.2.3. By Mode of Administration
      • 8.3.5.2.4. By End User

9. South America Pleurodynia Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Diagnosis
  • 9.2.2. By Treatment
  • 9.2.3. By Mode of Administration
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Pleurodynia Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Diagnosis
      • 9.3.1.2.2. By Treatment
      • 9.3.1.2.3. By Mode of Administration
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Pleurodynia Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Diagnosis
      • 9.3.2.2.2. By Treatment
      • 9.3.2.2.3. By Mode of Administration
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Pleurodynia Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Diagnosis
      • 9.3.3.2.2. By Treatment
      • 9.3.3.2.3. By Mode of Administration
      • 9.3.3.2.4. By End User

10. Middle East and Africa Pleurodynia Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Diagnosis
  • 10.2.2. By Treatment
  • 10.2.3. By Mode of Administration
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Pleurodynia Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Diagnosis
      • 10.3.1.2.2. By Treatment
      • 10.3.1.2.3. By Mode of Administration
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Pleurodynia Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Diagnosis
      • 10.3.2.2.2. By Treatment
      • 10.3.2.2.3. By Mode of Administration
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Pleurodynia Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Diagnosis
      • 10.3.3.2.2. By Treatment
      • 10.3.3.2.3. By Mode of Administration
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Pleurodynia Treatment Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Bristol-Myers Squibb Co
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. F. Hoffmann-La Roche Ltd
• 14.3. Pfizer Inc
• 14.4. Sanofi SA
• 14.5. Johnson & Johnson
• 14.6. Merck & Co Inc.
• 14.7. GlaxoSmithKline PLC
• 14.8. Reckitt Benckiser PLC
• 14.9. Bayer AG
• 14.10.Novartis AG

15. Strategic Recommendations